Nexxen International Ltd. (NEXN) Q3 2024 Earnings Call Transcript Summary
Nexxen International Ltd. (NEXN) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Nexxen International Ltd. (NEXN) Q3 2024 Earnings Call Transcript:
以下是Nexxen International Ltd.(NEXN)2024年第三季度业绩会交易简报:
Financial Performance:
财务表现:
Nexxen achieved Q3 contribution ex-TAC of $85.5 million, reflecting a 12% year-over-year growth.
Programmatic revenue reached $81.6 million, up 10% from Q3 2023, with CTV revenue growing 52% to $29.7 million.
Adjusted EBITDA was $31.6 million, growing 49% year-over-year, with margins increasing to 37% from 28%.
Non-IFRS diluted earnings per share increased to $0.14 in Q3 2024 from $0.09 in Q3 2023.
Nexxen实现了第三季度除去TAC后的贡献为8550万元,同比增长12%。
程序化营收达到了8160万元,比2023年第三季度增长了10%,CTV营收增长52%,达2970万元。
调整后的EBITDA为3160万元,同比增长49%,利润率从28%增至37%。
非IFRS摊薄每股收益从2023年第三季度的0.09美元增至2024年第三季度的0.14美元。
Business Progress:
业务进展:
Nexxen leveraged its end-to-end platform, emphasizing strong sales execution, and scaling partnerships under improved market conditions.
The company focused on technological advancements and integrated GenAI across its platform to enhance customer results and usability.
Nexxen充分利用其端到端平台,强调强大的销售执行能力,并在改善的市场环境下扩大合作伙伴关系。
该公司专注于技术进步,并在其平台上集成GenAI,以增强客户的成果和可用性。
Opportunities:
机会:
Expanding data capabilities and technological enhancements with GenAI.
Growing the media commerce segment with strategic partnerships and improving capabilities in data management and audience enrichment.
通过GenAI扩展数据能力和技术改进。
通过战略合作伙伴拓展媒体商务领域,并改善数据管理和受众丰富的能力。
Risks:
风险:
Potential impacts from macroeconomic conditions and privacy changes affecting data utilization and advertising effectiveness.
宏观经济条件和隐私变化可能会影响数据利用和广告效果。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由人工智能生成。内容准确性无法完全保证。如需更全面详情,请参阅IR网站。本文仅供投资者参考,不具有任何指导或推荐建议。